Advanced Refractive predicts first-quarter 2007 launch for novel cataract emulsifier:
This article was originally published in Clinica
Executive Summary
Advanced Refractive Technologies believes it could be set to file later this year a US marketing application for its next-generation cataract emulsifier. Its Accupulse device is novel in that it combines water-jet and ultrasound technologies, the company claims. Accupulse is to undergo animal studies designed to optimise the final design characteristics of the product and to prepare the device for FDA 510(k) approval. A 510(k) filing could be completed in the fourth quarter of 2006, with approval and initial sales occurring during the first quarter 2007, said Randy Bailey, the San Clemente, California firm's president and CEO. Around 18 million cataract surgeries are forecast for 2007, the company added.
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.